On Monday, September 30, the next meeting of the Transparency Council.
AOTMiT: Transparency Council on lung cancer and chronic kidney disease, among others
Published Sept. 30, 2024 07:39
Źródło: AOTMiT
The agenda includes:
- Preparation of a position paper on the legitimacy of qualifying the health care services "Excision of an intramural adenoma focus from the sinus of Douglas" and "Excision or destruction of a lesion in the sinus of Douglas - other" as guaranteed benefits.
- Preparation of a position paper on the reimbursement of Enspryng (satralizumabum) under the drug program: B.138.FM. "Treatment of patients with neuritis and myelitis spectrum disorder (NMOSD) (ICD-10: G36.0)".
- Preparation of a position paper on the reimbursement of Imjudo (tremelimumabum) in combination with Imfimzi (durvalumab) under the drug program "Treatment of patients with lung cancer (ICD- 10: C34) and pleural mesothelioma (ICD-10: C45)".
- Preparation of an opinion on continuation of reimbursement in off-label indications for active substances: Amiloridum + hydrochlorothiazidum for the indication: chronic kidney disease in children under 18 years of age.
Source: AOTMiT
